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Abstract A gene (hap) transcribed during the intra-erythrocytic
life cycle stages of the human malaria parasite Plasmodium
falciparum was cloned and sequenced. It was found to encode a
protein belonging to the aspartic proteinase family but which
carried replacements of catalytically crucial residues in the
hallmark sequences contributing to the active site of this type of
proteinase. Consideration is given as to whether this protein is
the first known parasite equivalent of the pregnancy-associated
glycoproteins that have been documented in ungulate mammals.
Alternatively, it may be operative as a new type of proteinase
with a distinct catalytic mechanism. In this event, since no
counterpart is known to exist in humans, it affords an attractive
potential target against which to develop new anti-malarial
drugs.
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1. Introduction
Aspartic proteinases contain two internally homologous do-
mains, each of which contributes a catalytic Asp residue to the
active site which is located between the two domains [1]. Each
aspartic acid residue is found in the hallmark sequence Vhy-
drophobic-hydrophobic-Asp-Thr/Ser-GlyV motif which, to-
gether with a further Vhydrophobic-hydrophobic-GlyV mo-
tif, forms a structural feature known as a psi-loop [2]. In some
enzymes, the domains are contained within a single polypep-
tide chain so that each of the motifs occurs twice within the
molecule and in the encoding gene [3]. Aspartic proteinases
are involved in a variety of protein processing functions in-
cluding protein catabolism and it is in this capacity that the
enzymes (plasmepsin I and plasmepsin II) from the human
malaria parasite Plasmodium falciparum act during the intra-
erythrocytic stages of parasite development. These two en-
zymes are critical in the pathway which breaks down host
cell haemoglobin to provide nutrients for the parasite growth
[4] and their inhibition results in parasite death [5,6].
In this report, we describe the sequence of a gene from P.
falciparum which is clearly a member of the aspartic protein-
ase gene family but which encodes a protein (HAP) that has
important variations from the conserved motifs of the aspartic
proteinases. Its potential for proteolytic activity is discussed
with reference to a three dimensional model.
2. Materials and methods
2.1. Identi¢cation and cloning of the hap gene
A V1149 library of EcoRI/HindIII digested DNA from P. falcipa-
rum strain HB3 was screened with an oligonucleotide, GGGTCACC-
TAGAATAAAGGTTG, designed from the sequence of the gene en-
coding proplasmepsin II. Several phage clones containing the same
970 bp insert were obtained. This fragment was excised from the
phage by digestion with EcoRI and HindIII before gel puri¢cation.
This DNA was made blunt-ended using the DNA polymerase I Kle-
now fragment prior to further digestion with RsaI, AluI or DraI. The
resulting fragments were cloned into SmaI cut, phosphatase-treated
pUC18 and transformed into Escherichia coli HB101. Clones were
sequenced and a contiguous sequence corresponding to the 3P end
of a gene, related to, but clearly di¡erent from those encoding pro-
plasmepsins I and II, was identi¢ed. No further clones were detected
when this insert was used as a probe to screen a variety of other P.
falciparum genomic and cDNA libraries. In order to clone sequences
5P to this fragment, a polymerase chain reaction (PCR)-based strategy
was employed using a speci¢c primer TTTACTTTCACAAGACTCT-
GATG, designed from the sequence of the initial clone, and a degen-
erate oligonucleotide primer ATTAAAAAATTAYATTAAAGAATC
which strongly corresponds to a region of the DNA sequence that is
conserved among the genes encoding P. falciparum proplasmepsin I
and proplasmepsin II and the Plasmodium berghei proplasmepsin
(equivalent to nucleotides 300^323 in Fig. 1). These primers were
used in a PCR ampli¢cation with P. falciparum total genomic DNA
as template. The 234 bp amplicon was cloned into pUC18 using the
Sureclone PCR cloning kit (Pharmacia) and sequenced. This clone
extended the sequence of the gene by a further 115 nucleotides in
the 5P direction. The gene sequence was completed using inverse
PCR. Genomic DNA was digested with Sau3AI and the enzyme
was heat-inactivated before overnight ligation of the products at
16‡C. PCR was performed using the primers TTCCACATTAT-
CAAACTCACTACC (nucleotides 390^367, Fig. 1) and GCAAATG-
TATTATCTTTTGGAGAGG (nucleotides 404^427), through 40
cycles with annealing at 60‡C. The PCR products were gel-puri¢ed
and ligated into pGEM-T (Promega) resulting in several related clones
in which various rearrangements, duplications and deletions were evi-
dent. The sequence of the longest clone extended only four nucleotides
upstream of the proposed initiating Met codon but no Sau3AI site
remnant was apparent. Comparison of these clones enabled the con-
struction of a consensus sequence for the 5P end of the gene. The
extreme instability of clones containing a 5P non-coding sequence ex-
plains the di⁄culty in isolating a full length clone of this gene from
conventional gene libraries.
2.2. Expression of recombinant HAP
In order to produce recombinant HAP protein, a truncated form of
the precursor protein (semi-proHAP) was expressed in E. coli using
the strategy described previously for plasmepsins I and II [6,7]. A
fragment of the hap gene encoding amino acids 76^451 (Fig. 1) was
ampli¢ed in a PCR reaction using the primers CCGGAATTCG-
GATCCAAATATTCGACAGTAGGATTT and GCGAGCATGC-
GGATCCTTAGTTTTTTGCAACTGCAAAACC. This amplicon
was cloned into the expression vector pET3a for the induction of
protein synthesis in E. coli BL21DE3(pLysS). The recombinant ma-
terial produced was insoluble and so was dissolved in bu¡er (100 mM
Tris-HCl, pH 8.0, 1 mM glycine, 1 mM EDTA, 50 mM L-mercapto-
ethanol) containing 6 M urea and refolding was attempted as de-
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scribed previously using the conditions employed with recombinant
proplasmepsin I [6] and proplasmepsin II [7].
2.3. Northern blot analysis
Isolation of stage-speci¢c RNA from P. falciparum strain K1 and
Northern blot analysis were carried out as described previously [6]
using most of the hap gene (nucleotides 310^1428, Fig. 1) as a probe
to detect hap-speci¢c transcripts.
2.4. Reverse transcriptase (RT-) PCR
Messenger RNA from intra-erythrocytic stage parasites was reverse
transcribed prior to PCR using the degenerate antisense strand oligo-
nucleotide TRSATCTAAAKYWAYTTGCCA (nucleotides 966^946
Fig. 1) in combination with TGGTCAAAAATTTAATTTCTTATTC
(nucleotides 444^468 Fig. 1) to amplify hap sequences.
To ensure that any ampli¢cation products had arisen from the
presence of message-speci¢c cDNA (rather than contaminating ge-
nomic DNA that would have generated false positive results), a con-
trol PCR reaction was performed with the P. falciparum DNA polym-
erase K-speci¢c primers TTTATGGTTGTTTAGGA and GAAGC-
ATCTTCACTCGT. These were used in separate ampli¢cation reac-
tions with the cDNA and genomic DNA as templates. The gene
encoding DNA polymerase K contains a 200 bp intron [8] between
these primer binding sites. Therefore it was possible to distinguish
between PCR products originating from cDNA (700 bp) and those
derived from genomic DNA (900 bp). The data (not shown) indicated
that the cDNA was uncontaminated with genomic DNA.
2.5. Modelling
A three dimensional model of ‘mature’ HAP (amino acid residues
125^451, Fig. 1) was constructed on a Silicon Graphics O2 worksta-
tion using Moloc [9] and plasmepsin II (PDB code 1sme, [10]) as the
template structure. The quality of the model was checked with a
program developed by Luethy et al. [11].
3. Results and discussion
3.1. hap isolation and sequence comparisons
As described in Section 2, an open reading frame of 1353
nucleotides was cloned which is predicted to encode a 53 kDa
protein consisting of 451 amino acids. This protein is related
to but clearly distinct from proplasmepsin I [12] and proplas-
mepsin II [13] from P. falciparum, having identities of 60 and
56%, respectively, with these zymogens (Fig. 2). By analogy
with the proplasmepsins, the product of the hap gene is pre-
dicted to be a precursor protein (proHAP) with a propart
approximately 123 residues long that includes a stretch of
19 hydrophobic amino acids (residues 40^58, Fig. 1). Compar-
able proparts have been identi¢ed in proplasmepsins I and II
and, in their sequences, the corresponding hydrophobic region
has been implicated in type II membrane anchoring [14]. By
contrast, the proparts of mammalian/fungal aspartic protein-
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Fig. 1. Sequence of the hap gene. The nucleotide sequence of the hap gene (EMBL accession number AJ009990) with translation. The His-Thr-
Ala and Asp-Ser-Ala motifs at the centre of the interdomain cleft are shown double underlined whilst the Vhydrophobic-hydrophobic-GlyV
motifs, which interact with the former in the psi-loop structures, are underlined.
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ases do not contain such a membrane spanning sequence and
are only V50 amino acids in length.
The region predicted to correspond to mature HAP (resi-
dues 124^451, Fig. 1) shares 64 and 61% identity, respectively,
with the mature enzymes, plasmepsin I and plasmepsin II. A
model of HAP was constructed using the crystallographically
determined structure of plasmepsin II as a template. Due to
the high sequence identity, the HAP model exhibits many of
the major structural features of the aspartic proteinases. Since
there are no insertions or deletions in the HAP sequence
compared to that of plasmepsin II, it is reasonable to assume
that the backbone of HAP is very similar. The so-called ‘¢re-
man’s grip’ interaction [15] which is located at the interface
between the two domains is maintained in HAP. In contrast,
the psi-loops in each domain that generate the catalytic appa-
ratus intrinsic to an aspartic proteinase by the interaction of
the essential VAsp-Thr/Ser-GlyV and Vhydrophobic-hy-
drophobic-GlyV motifs (see Section 1), are distinctly di¡er-
ent in HAP. Both of the Vhydrophobic-hydrophobic-GlyV
motifs are present within both domains (underlined, Fig. 1).
The VAsp-215-Thr/Ser-216-Gly-217V motif (pepsin num-
bering) of the C-terminal domain is slightly modi¢ed in
HAP to VAsp-Ser-AlaV (Fig. 2). Even more striking, how-
ever, is the alteration of the motif in the N-terminal domain
from VAsp-32-Thr-33-Gly-34V (pepsin numbering) to
VHis-Thr-AlaV. This eliminates one of the aspartic acid
residues which is essential for the operation of the catalytic
mechanism of an aspartic proteinase. These features within
the catalytic apparatus of the Plasmodium protein suggest
that it might be termed as a histo-aspartic protein (HAP).
The model indicates that free rotation of the imidazole ring
of the His-32 residue may be prevented by the positions of the
side chains of Ala-34 and Ala-217 (pepsin numbering, Fig. 3).
Such steric hindrance to hold His-32 in place may be impor-
tant if this residue is involved in a catalytic role in HAP.
A further major deviation from an aspartic proteinase motif
is evident in the L-hairpin loop (frequently termed the ‘£ap’)
that lies over the active site cleft and closes when substrate is
bound, making extensive contacts with bound substrates and
inhibitors [15]. In typical mammalian/fungal aspartic protein-
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Fig. 2. Sequence alignment of proHAP with members of the as-
partic proteinase family. The predicted translation product of the
hap gene (ProHAP) is aligned with proplasmepsin I (ProPMI) and
proplasmepsin II (ProPMII), also from P. falciparum. Residues
which are identical in two or more sequences are shaded. Dashes
represent spaces included to optimise the alignments. The sequence
of pig pre-propepsin is included for reference and key residues in
this enzyme Asp-32, Trp-39, Tyr-75 and Asp-215 are identi¢ed ac-
cording to the standard numbering system for mature pepsin.
Fig. 3. Residues at the centre of the interdomain cleft of HAP. Residues 30^35 (VL-F-H-T-AV) and 215^218 (VD-S-A-TV) in HAP corre-
sponding to the active site sequence motifs of conventional aspartic proteinases (numbering is based on that of pig pepsin). His-32 and As-
p215 are shown in yellow, with Ala-33 and Ala-216 in white. Molecular surfaces are illustrated for His-32, Ala-33 and Ala-215 to indicate the
constraint placed on rotation of the imidazole ring by the two Ala residues.
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ases, this £ap contains the sequence VTyr-75-Gly-X-GlyV
(where X is often Ser, Thr or Asp). In plasmepsins I and II,
this sequence is slightly altered to VTyr-Val-Ser-GlyV. In
HAP, the counterpart sequence of residues is VSer-Lys-
Ala-GlyV. The side chain of Tyr-75 has an important role
in H-bonding with the invariant Trp-39 to hold the £ap closed
when substrate is bound and it also divides the S1 and S2’
subsite pockets [16,17]. The side chain of the Ser in HAP
would be unable to mimic the action of Tyr-75 as it would
be too short to form the necessary H-bond with Trp-39
(which is retained in the sequence of HAP, Fig. 1) and it
would not be able to form a wall between the substrate res-
idues occupying the S1 and S2’ pockets. Attempts to replace
Tyr-75 in aspartic proteinases with virtually any other amino
acid results in a dramatic reduction in enzyme activity, e.g. its
replacement by Ser in Rhizomucor pusillus pepsin led to at
least a 1000-fold reduction in proteolytic activity and ap-
peared to constrain the general aspartic proteinase inhibitor,
pepstatin, to bind in a di¡erent conformation to the mutant
enzyme [16]. Lys-76 in HAP is also unusual as it replaces the
largely conserved Gly-76 residue of most aspartic proteinases
with a positively charged residue. The side chain of residue 77
of aspartic proteinases usually has a H-bond accepting a func-
tion (Ser, Thr, Asp) which allows interactions with a back-
bone NH of substrates or peptidic inhibitors. The Ala in this
location in HAP would be unable to contribute to such an
interaction.
In addition to the catalytically active aspartic proteinases, a
family of closely related proteins is expressed in ungulate
(hoofed) mammals during pregnancy [18]. For example, one
such a pregnancy-associated glycoprotein of ovine origin (ov-
PAG-1) shares approximately 50% identity with pepsin but
lacks one of the two catalytic Asp residues (Asp-215 pepsin
numbering) whilst a bovine homologue (boPAG-1) has an
alanine in place of the conserved glycine at position 34 in
the ¢rst VAsp-Thr-GlyV motif. Models of these proteins
(constructed on the basis of the known crystal structures of
porcine pepsin and bovine chymosin) indicate that both are
likely to be catalytically inactive [19] but, as both can bind
pepstatin, it has been suggested that their binding sites are still
viable and they may perform some function by binding spe-
ci¢cally to other proteins [18].
The pregnancy associated glycoproteins (PAGs) have sev-
eral features in common with HAP, for instance, the highly
conserved Vhydrophobic-hydrophobic-Gly motifs which
form a part of the psi-loops. In addition, some of the residues
that make HAP unusual are also changed in the PAGs as
illustrated in Table 1. It can be seen that Gly-34 of the as-
partic proteinases is Ala in HAP and in boPAG1, poPAG1
and ovPAG3 also [19,20]. Guruprasad et al. [19] speculated
that this alteration may render these PAGs proteolytically
inactive due to displacement of the catalytic water molecule
immobilised between Asp-32 and Asp-215. However, in rabbit
cathepsin E, the same Gly-34 is replaced by the much larger
Val and this enzyme is still able to cleave substrates with the
same e⁄ciency as cathepsin E from other species which retain
Gly-34 [21]. The replacement of Asp-32 by His has not been
reported in the PAGs to date but Asp-215 is changed to His
in boPAG9 [22]. Unusual residues have also been detected at
positions 75^77 on the £ap of several PAGs (Table 1) as
described above for HAP. Thus, a role for HAP as a binding
protein similar to the mammalian pregnancy-associated glyco-
proteins may be postulated. The binding cleft in HAP, like
those of the closely related true aspartic proteinases plasmep-
sin I and plasmepsin II, is rather hydrophobic which may
indicate a preference in HAP for a hydrophobic ligand(s) in
this protein-binding scenario.
3.2. Expression of the hap gene
A RT-PCR was performed, using the primers described in
Section 2, on parasitic mRNA extracted from intra-erythro-
cytic stages and a 522 bp product was cloned and sequenced.
This was established unequivocally to have been derived from
mRNA and not contaminating genomic DNA by carrying put
the control PCR on DNA polymerase K, as described in Sec-
tion 2. It was thus demonstrated that the hap gene is actively
transcribed. This is consistent with the fact that P. falciparum
appears to have minimised the content of non-functional
DNA in its genome, with an early survey showing only three
out of 20 genes to contain any intronic sequences [23].
FEBS 21744 22-3-99 Cyaan Magenta Geel Zwart
Table 1
Substitution of conserved aspartic proteinase features in HAP-selected pregnancy-associated glycoproteins (Xie et al., 1997; Szafranska et al.,
1995)
Residues (pepsin number) Protein Amino acid(s)
13 Typical AP Glu/Gln
HAP Leu
Plasmepsin I and II Met
ovPAGs 1, 8, 9 Leu
32^35 Typical AP Asp-Thr-Gly
HAP His-Thr-Ala
boPAG1, poPAG1, ovPAG3 Asp-Thr-Ala
Rabbit CatE Asp-Thr-Val
75^77 Typical AP Tyr-Gly-Ser/Thr/Asp
HAP Ser-Lys-Ala
poPAG1 Pro-His-Ser
boPAG10 Tyr-Thr-Ala
215^217 Typical AP Asp-Thr/Ser-Gly
HAP Asp-Ser-Ala
boPAG9 His-Thr-Gly
Numbering of amino acids is based on that of pig pepsin.
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Changes in the expression of the hap gene during the intra-
erythrocytic cycle were detected by Northern blot analysis of
synchronised blood stage cultures (Fig. 4). mRNA levels for
hap peaked during the mid to late trophozoite stage of the
growth cycle with minima during the ring and schizont stages.
This is a similar expression pattern to that observed previ-
ously for the proplasmepsin II gene [6].
It is thus clear that transcription of the hap gene produces a
full length mRNA and there is no a priori reason why this
should not be translated in frame to generate a proHAP pro-
tein comparable in length to aspartic proteinase precursors
such as proplasmepsin I and proplasmepsin II. The identi¢ca-
tion of HAP protein in parasites requires an antiserum speci¢c
for this protein and which does not cross react with plasmep-
sins I or II. Identities greater than 60% between HAP and
these two plasmepsins have prevented the production of
such a selective antiserum to date. With this restriction, iden-
ti¢cation of HAP protein in naturally occurring extracts pre-
pared from parasites at appropriate stages is not a viable
option. This, together with the paucity of material likely to
be extracted, indicated that a recombinant approach would be
more likely to generate the amounts of HAP required for
studies of peptide/protein-binding and catalysis. Plasmepsin
II is readily generated by auto-activation of recombinant pro-
plasmepsin II produced in E. coli [7]. However, considerably
greater di⁄culties were encountered, with very low yields of
active enzyme, when this approach was applied to recombi-
nant proplasmepsin I [6]. Re£ecting the latter situation, ex-
pression of the hap gene in E. coli generated large amounts (10
mg/l) of recombinant semi-proHAP in an insoluble form, but
although refolding was attempted, no activity was seen (data
not shown). Thus, the production of properly folded HAP
may require the use of a heterologous system such as P. pas-
toris.
The replacement of one of the catalytic Asp residues of an
aspartic proteinase by a His residue means that, of necessity,
HAP cannot operate through the type of catalytic mechanism
employed by archetypal and retroviral aspartic proteinases
[24^26]. If HAP is active as a proteinase, then it would be
required to operate through a completely novel catalytic
mechanism and would thus represent a new class of (histo-
aspartic) proteinase. The combination of all of the residue
replacements described above for HAP relative to the aspartic
proteinases, may act in a compensatory fashion such that
hydrolysis of a scissile peptide bond would still be facilitated
by the protein but the distinct residues in the catalytic con-
stellation of HAP would a¡ord a distinctly novel opportunity
for drug design targeted against this unique parasite protein.
If, like the PAGs on the other hand, HAP is not active pro-
teolytically, then it represents the ¢rst such protein to be iden-
ti¢ed from a species other than ungulate mammals and may
have a role, as yet unidenti¢ed, in binding proteins. Resolu-
tion between these intriguing possibilities is the subject of on-
going investigations.
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